OCX OncoCyte
- 2.7600
- -0.1700-5.80%
OncoCyte News
4 Analysts Assess OncoCyte: What You Need To Know
Analysts' ratings for OncoCyte (NASDAQ:OCX) over the last quarter vary from bullish to bearish, as provided by 4 analysts.The table below summarizes their recent ratings, showcasing the evolving senti
Needham: Reiterated OncoCyte (OCX.US) rating, adjusted from buy to buy rating, target price $4.25.
Needham: Reiterated OncoCyte (OCX.US) rating, adjusted from buy to buy rating, target price $4.25.
Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target
Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.
OncoCyte's Strategic Initiatives and Financial Health Garner Buy Rating
Earnings Call Summary | OncoCyte(OCX.US) Q1 2024 Earnings Conference
The following is a summary of the OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript:Financial Performance:OncoCyte reported a net revenue of $176,000 in Q1 2024, marking a 41% decrease from
OncoCyte Q1 2024 GAAP EPS $(1.13) Misses $(0.67) Estimate, Sales $176.000K Miss $350.000K Estimate
OncoCyte (NASDAQ:OCX) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.67) by 68.66 percent. This is a 237.8 percent decrease over earnings of $0.82 pe
OncoCyte | 10-Q: Quarterly report
Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q1 Revenue $176,000, Vs. Street Est of $0.4M
04:08 PM EDT, 05/15/2024 (MT Newswires) -- Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q1 Revenue $176,000, vs. Street Est of $0.4M
Oncocyte 1Q Loss/Shr $1.13 >OCX
Oncocyte 1Q Loss/Shr $1.13 >OCX
Press Release: Oncocyte Reports First Quarter 2024 Financial Results
Oncocyte Reports First Quarter 2024 Financial Results Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation
OncoCyte Files to Sell 5.42M Shares of Common Stock for Holders
Oncocyte to Announce First Quarter 2024 Financial Results
IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday,
PRISM MarketView Spotlights Oncocyte Corporation as It Works to Disrupt the Precision Diagnostics Marketplace
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation's Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature
Oncocyte Price Target Raised to $4.25/Share From $3.60 by Needham
Oncocyte Price Target Raised to $4.25/Share From $3.60 by Needham
Oncocyte Is Maintained at Buy by Needham
Oncocyte Is Maintained at Buy by Needham
Needham: Maintaining the OncoCyte (OCX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.60 to $4.25.
Needham: Maintaining the OncoCyte (OCX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.60 to $4.25.
Needham Maintains Buy on OncoCyte, Raises Price Target to $4.25
Needham analyst Mike Matson maintains OncoCyte with a Buy and raises the price target from $3.6 to $4.25.
Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. The company's market cap stands at $4.4 billion. Nuwellis (NASDAQ:NUWE) shares increased by
Bio-Rad Laboratories Inc Reports 8.99% Passive Stake In Oncocyte Corp As Of April 15, 2024
Bio-Rad Laboratories Inc Reports 8.99% Passive Stake In Oncocyte Corp As Of April 15, 2024
Analysis
Price Target
No Data
